Eris Lifesciences Limited Total Assets
Eris Lifesciences Limited total assets. Based on the latest financial reports, Eris Lifesciences Limited (ERIS) holds total assets worth Rs73.66 Billion INR (≈ $796.55 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Eris Lifesciences Limited market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Eris Lifesciences Limited (2012–2026)
Total assets of Eris Lifesciences Limited from 2012 to 2026. This chart illustrates how Eris Lifesciences Limited's total assets have evolved over time, based on quarterly financial data. See latest Eris Lifesciences Limited stock price today for real-time trading data and today's change.
Eris Lifesciences Limited - Asset Composition Analysis
Eris Lifesciences Limited Total Assets Breakdown (March 2026)
Eris Lifesciences Limited total assets breakdown as of March 2026. Eris Lifesciences Limited's total assets of Rs73.66 Billion consist of 20.9% current assets and 79.1% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0.9% |
| Accounts Receivable | Rs7.33 Billion | 10.0% |
| Inventory | Rs4.37 Billion | 5.9% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs35.67 Billion | 48.4% |
| Goodwill | Rs9.12 Billion | 12.4% |
Asset Composition Trend (2012–2026)
This chart illustrates how Eris Lifesciences Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Eris Lifesciences Limited short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eris Lifesciences Limited's current assets represent 20.9% of total assets in 2026, a decrease from 67.9% in 2012.
- Cash Position: Cash and equivalents constituted 0.9% of total assets in 2026, down from 9.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 60.0% of total assets, an increase from 3.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 48.4% of total assets.
Eris Lifesciences Limited Competitors by Total Assets
Key competitors of Eris Lifesciences Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Eris Lifesciences Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.74 | 0.89 | 2.80 |
| Quick Ratio | 0.53 | 0.64 | 2.23 |
| Cash Ratio | 0.00 | 0.02 | 0.00 |
| Working Capital | Rs-5.37 Billion | Rs-1.58 Billion | Rs3.00 Billion |
Eris Lifesciences Limited - Advanced Valuation Insights
This section examines the relationship between Eris Lifesciences Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.95 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 4.7% |
| Total Assets | Rs73.66 Billion |
| Market Capitalization | $1.77 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Eris Lifesciences Limited's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Eris Lifesciences Limited's assets grew by 4.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Eris Lifesciences Limited (2012–2026)
The table below shows the annual total assets of Eris Lifesciences Limited from 2012 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs73.66 Billion ≈ $796.55 Million |
+4.73% |
| 2025-03-31 | Rs70.33 Billion ≈ $760.61 Million |
-0.22% |
| 2024-03-31 | Rs70.49 Billion ≈ $762.30 Million |
+92.21% |
| 2023-03-31 | Rs36.67 Billion ≈ $396.61 Million |
+61.40% |
| 2022-03-31 | Rs22.72 Billion ≈ $245.72 Million |
+23.84% |
| 2021-03-31 | Rs18.35 Billion ≈ $198.42 Million |
+18.20% |
| 2020-03-31 | Rs15.52 Billion ≈ $167.88 Million |
-0.09% |
| 2019-03-31 | Rs15.54 Billion ≈ $168.02 Million |
+6.41% |
| 2018-03-31 | Rs14.60 Billion ≈ $157.90 Million |
+127.78% |
| 2017-03-31 | Rs6.41 Billion ≈ $69.32 Million |
+53.14% |
| 2016-03-31 | Rs4.19 Billion ≈ $45.27 Million |
+17.16% |
| 2015-03-31 | Rs3.57 Billion ≈ $38.64 Million |
+32.03% |
| 2014-03-31 | Rs2.71 Billion ≈ $29.26 Million |
+57.50% |
| 2013-03-31 | Rs1.72 Billion ≈ $18.58 Million |
+68.35% |
| 2012-03-31 | Rs1.02 Billion ≈ $11.04 Million |
-- |
About Eris Lifesciences Limited
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti"diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women… Read more